Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesResidual cardiovascular risk in treated hypertension and hyperlipidaemia: The PRIME Study
Journal of Human Hypertension, 06/03/09
Blacher J et al. – Treatment with antihypertensive agents, but not with lipid-lowering agents, was associated with a sizeable residual cardiovascular risk, suggesting that more efficient risk reduction strategies in hypertension should be developed as a priority.
Methods- Study of the degree of cardiovascular risk remaining in hypertension and dyslipidaemia pts treated pharmacologically
- Assessment of levels of risk factors achieved that is 'residual cardiovascular risk'
- Use of data from the Prospective Epidemiological Study of Myocardial Infarction (PRIME)
- PRIME subjects: 9649 men age 50–59 yrs, from France and Northern Ireland with 10-yr follow-up
- PRIME tested presence of specific residual cardiovascular risks of coronary heart disease, stroke, total of fatal and non-fatal cardiovascular events and cardiovascular mortality, in pts treated with antihypertensive agents or lipid-lowering agents
- In whole cohort, 796 pts developed fatal or non-fatal cardiovascular event
- Antihypertensive drug use at baseline significantly associated with total cardiovascular event risk, but not lipid-lowering drug use, after adjusting for classic risk factors
- Adjusted classic risk factors: age, smoking, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure and diabetes
- Similar results for coronary heart disease, stroke, and cardiovascular death, but neither for total death nor for non-cardiovascular death
- For any cardiovascular endpoint, residual risks did not globally differ by antihypertensive drug class prescribed at baseline
Today in Atherosclerosis/Lipids...keeping you current
Receive free subspecialty "5-minute updates" via email
Smoking intensity and lipoprotein abnormalities in active smokers
Journal of Clinical Lipidology, 12/20/09
Influence of Genetic Polymorphism in Matrix Metalloproteinase-3 on Extent of Coronary Atherosclerosis and Risk of Coronary Artery Stenosis
Archives of Medical Research, 12/20/09
Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
Lipids in Health and Disease, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor